Genflow Biosciences PLC (LSE:GENF, OTCQB:GENFF) CEO Dr Eric Leire talked with Proactive's Stephen Gunnion about the company receiving €395,847, representing 50% of the Exofastrack research grant from the Government of Wallonia in Belgium's Advanced Therapy Medicinal Products (ATMPs).
Leire explained that the grant, a non-dilutive, non-reimbursable subsidy, supports Genflow and EXO Biologics' three-year scientific program.
Covering 80% of the expenses, the grant will be used for working capital. The program will deliver a therapeutic product composed of exosomes encapsulating an AAV or mRNA encoding SIRT6. The exosome therapy will be designed to target liver fibrosis (MASH) and Werner Syndrome, an accelerated ageing disease.
Discussing the program, Leire highlighted the potential of exosomes in addressing unmet medical needs and mentioned the innovative photo operation technique for loading exosomes. If successful, this technique could have significant commercial implications beyond the initial progeria research.
For more updates on Genflow Biosciences' groundbreaking research, visit Proactive's YouTube channel, give this video a like, subscribe to the channel, and enable notifications for future content.
#GenflowBiosciences #ExosomeTherapy #AgingResearch #DrEricLeire #BiotechFunding #InnovativeMedicine #PhotoOperation #NonDilutiveFunding #ProactiveInterviews
#ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews
